Study Evaluating Etanercept in Patients With Rheumatoid Arthritis(RA), Juvenile Idiopathic Arthritis (JIA), or Psoriatic Arthritis (PsA) in Spain

N/ACompletedNCT00195377

Wyeth is now a wholly owned subsidiary of Pfizer1,000 enrolled

Overview

The purpose of this study is to assess the safety of etanercept in patients with rheumatoid arthritis (RA), juvenile idiopathic arthritis (JIA) or psoriatic arthritis (PsA) in Spain

Study Type

OBSERVATIONAL

Enrollment

1,000

Conditions

Arthritis, Psoriatic Arthritis, Rheumatoid

Interventions

EtanerceptDRUG

Eligibility

Sex: ALLMin age: 4 Years

Medical Language ↔ Plain English

Inclusion Criteria: * RA or PsA in whom DMARDs/antiTNF antibodies/anti IL1 has been insufficient or inappropriate * Children from 4 to 17 years old with JIA polyarticular Exclusion Criteria: * Clinically significant abnormal screening lab values * Patients who are planning to undergo elective surgery during the study period. * Other current autoimmune connective tissue diseases

Locations (1)

Unnamed facility

Madrid, Madrid, Spain

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.